Purpose of this Study
We are doing this study to find out how well an experimental multi-cancer early detection (MCED) test works. We want to know if this test is accurate and if it provides a good benefit for study participants and medical providers.
Who Can Participate?
Eligibility
Adults who are 50 years or older.
For more information about who can be in this study, please contact the study team at DukeOnco-PrimaryCare@duke.edu.
For more information about who can be in this study, please contact the study team at DukeOnco-PrimaryCare@duke.edu.
Age Range
50-79
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
Yes
What is Involved?
If you choose to join this study, you will:
- Answer questionnaires
- Have a blood draw
If your test shows a result of "cancer signal detected," the study doctor or your regular doctor might order additional tests for you.
We will pay you for your time on the study.
- Answer questionnaires
- Have a blood draw
If your test shows a result of "cancer signal detected," the study doctor or your regular doctor might order additional tests for you.
We will pay you for your time on the study.
Locations
Duke University Hospital
Pickett Road Research
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL
Multi-Cancer Early Detection Test in an Eligible Screening Population
Multi-Cancer Early Detection Test in an Eligible Screening Population
Study Website
Principal Investigator
Kevin
Oeffinger
Protocol Number
PRO00109985
NCT ID
NCT05155605
Phase
N/A
Enrollment Status
OPEN TO ACCRUAL